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Scianna: the lucky 13th blood group system
P.A.R. Brunker and W.A. Flegel
The Scianna system was named in 1974 when it was appreciated 
that two antibodies described in 1962 in fact identified antithetical 
antigens. However, it was not until 2003 that the protein on 
which antigens of this system are found and the first molecular 
variants were described. Scianna was the last previously 
serologically defined, protein-based blood group system to be 
characterized at the molecular level, marking the end of an era 
in immunohematology. This story highlights the critical role 
that availability of laboratory reagents for serologic testing has 
played in the initial characterization of a blood group and sets the 
stage for the development of new reagents, such as recombinant 
proteins, to assist in this process. The central role that genetics 
has played, both by classical pedigree analysis and by molecular 
techniques, in the discovery and characterization of this blood 
group is reviewed. Immunohematology 2011;27:41–57.
The high- and low-prevalence antigens that constitute 
the Scianna (SC) blood group system are caused by 
variants in the erythroid membrane–associated protein 
(ERMAP).1 SC was initially identified by serologic methods; 
the clinical significance of antibodies specific to SC is 
uncertain, although case reports demonstrating rare cases 
of hemolytic disease attributed to SC variants exist. Genetic 
analyses in both the classical and molecular approaches, 
have been central to the discovery and elaboration of the 
SC system. This article reviews the story of the SC blood 
group from a genetic point of view, emphasizing the way it 
has been brought into focus thanks to genetic tools ranging 
from pedigree analysis to physical mapping.
History
Nomenclature: Sc1, Sc2, Sc3, and Sc4
The story of the 13th International Society of Blood 
Transfusion (ISBT) blood group system began in 1962, 
when a new high-prevalence antigen was reported alongside 
a coexisting anti-D in a 25-year-old, multiparous woman 
of Italian descent in Miami, Florida, who experienced 
several fetal deaths as a result of hemolytic disease of the 
fetus and newborn (HDFN).2 She came to clinical attention 
because of difficulty obtaining compatible blood. Her ABO 
and Rh typings were O ccddee, and her husband’s were O 
CCDee. After an unremarkable first pregnancy and birth, 
she experienced three subsequent and progressively earlier 
fetal demises—at term, at 7, and at 6 months’ gestation—
in the late 1950s. After her second fetal death, her anti-D 
titer was demonstrated at 256, and the new antibody to a 
high-prevalence antigen, originally named anti-Sm, was 
demonstrated at a titer of 16. An informative family study 
revealed three antigen-negative siblings with a likely 
autosomal dominant mode of antigen inheritance, and no 
unrelated antigen-negative specimens were identified in a 
population survey of 600 D– random individuals. A clue 
to the genetic position of the responsible locus was present 
even in this defining family: based on the pedigree, it could 
not be determined whether the new antigen was part of the 
Rh system as it was in linkage disequilibrium with cc in 
that kindred.
In spite of this very dramatic introduction, the clinical 
importance of the new antigen was uncertain, as the 
concurrent anti-D clearly could account for the proband’s 
unfortunate obstetric history. While the work of the Miami 
group was in the pipeline for publication, the Winnipeg Rh 
Laboratory, in Manitoba, reported an antibody to a new 
low-prevalence antigen arising in a 50-year-old man with 
stomach cancer.3 In this patient, the antibody originally 
named anti-Bua, found in serum Char., was identified during 
a routine pretransfusion crossmatch. As the patient had 
been transfused with three units of blood 14 days earlier, 
this delayed serologic transfusion reaction was investigated, 
which revealed that although his serum was crossmatch-
compatible with all three donor samples before transfusion, 
it reacted with one of the three samples after transfusion. 
A follow-up survey of 18 panel red blood cells (RBCs) 
demonstrated one reactive cell, suggesting a relatively high 
prevalence for this new antigen; however, this proved not to 
be the case, as only one of the next 1,000 donors was positive. 
The families of all three of these probands took part in 
pedigree analysis, one of which was extremely informative, 
with a kindred of both parents and nine offspring. These 
studies in classical genetics demonstrated that the new 
locus segregated independently from ABO, MNSs, P, Rh, 
Kell, Kidd, Duffy, and X-chromosome.
Genetics and Inheritance
It did not take long for the relationship between the Sm 
and Bua to be postulated, tested, and proven. In 1964, the 
anti-Bua serum was used to type the available members of 
the index Sm family (Fig. 1). The importance of using this 
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serum as a typing reagent is underscored by 
the fact that it was required to demonstrate 
that the parent generation consists of 
a mating of two Sm/Bua heterozygotes 
(parents PM Sr. and RM): the F1 generation 
consists of four Sm– homozygotes, one 
Sm/Bua heterozygote (individual AM), 
and one Bua/Bua homozygote (individual 
CS). Without it, the zygosities of AM 
and CS could not be determined. This is 
the only outbred family in the Sm/Bua 
literature in which both parents are  Sm/
Bua heterozygotes.
Concurrent with their suggestion 
that Sm and Bua were the result of a 
biallelic polymorphism, the Winnipeg Rh 
Laboratory also reported an extensive 
study of a Mennonite population in whom 
the Bua antigen had a considerably higher 
frequency of 5 in 348 samples than the 
1 in 1,000 prevalence observed in other 
Caucasian populations.4,5 Although they 
tested 145 Caucasian families for Bua and 
rigorously examined 19 based on the presence of Bua, it was 
not until additional reagent serum was available in 1966 
that definitive proof of this relationship was found.
Further examples of anti-Bua were discovered in a 
group of individuals from Poland and the United Kingdom 
(particularly the strongest serum Soch.) who had produced 
anti-Bua after having been artificially immunized with D+ 
cells to stimulate the production of Rh antibodies.6 Through 
a careful study of the donors used for these stimulations, 
three additional subjects who were also stimulated with 
these cells were found to have created an anti-Bua, although 
it was much weaker than that in the Soch. serum. The 
prevalence of the Bua allele was determined as 0.88 percent 
in a Warsaw and 0.67 percent in a London cohort.
Using this reagent after adsorption to remove the 
iatrogenically generated anti-D also present in the serum, 
the Winnipeg Rh Laboratory identified a large, six-
generation Mennonite kindred that included two cousin 
matings of Sm/Bua heterozygotes, which produced 20 
offspring.7 Through a methodical review of the serologic 
data from samples from the kindred, which showed the 
effects of antibody dosage on antigen expression, this report 
confirmed and expanded the definition of the new system 
to exclude all blood groups reported before 1962 (except 
Diego, Yt, and Auberger) and Doa and Csa. Independence 
from Yt was established in two British families.8,9 Finally, 
the currently accepted nomenclature (Table 1) was proposed 
in 1974 to reflect the surname of the index family in the 
Table 1.  Alleles, encoded antigens, and ISBT terminology of the Scianna blood group 
system
Wild-type Variant







Sc1 Sca (Sm) SC*01 169g 57Gly Sc1
Sc2 Scb (Bua) SC*02 169a 57Arg Sc2
Sc3 Sc null SC*03N.01† 307D2 Frameshift: null
Sc3 Sc null 994c 332Arg SC*03N.02† 994t
332Stop: 
null
Sc4 Rd 178c 60Pro Rd– SC*04 178g
60Ala 
Rd+
Sc5 STAR 139g 47Glu STAR+ SC*05 139a
47Lys 
STAR–
Sc6 SCER 242g 81Arg SCER+ SC*06 242a
81Gln 
SCER–
Sc7 SCAN 103g 35Gly SCAN+ SC*07 103a
35Ser 
SCAN–
† Provisional name suggested by the International Society of Blood Transfusion (ISBT) Working 
Party on Red Cell Immunogenetics and Blood Group Terminology
Fig. 1 Index family in the characterization of the Sm antigen and 
demonstration of the antithetical relationship between Sm and Bua 
antigens. The proband (patient Ms. Scianna) is indicated by the 
arrow. Solid color represents Sm+ (Sc:1+) antigen test. Striped fill 
represents Bua+ (Sc:2+) antigen test. Inferred genotype is shown 
below the symbol for each family member. The proband’s parents 
were deceased at the time of Bua testing, so are inferred to be 
heterozygotes, indicated by the interrupted stripes and parentheses 
in their genotype designation. The combination of Sm and Bua typing 
confirms that subject AM is a heterozygote, which was suggested 
by observations of dosage effects in serologic testing. (Redrawn 
with data from references 2 and 4.)
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discovery of anti-Sm, Scianna,10 such that Sm was renamed 
Sc1 and Bua was renamed Sc2.
The SC Gene Lies on Chromosome 1
The focus then shifted from definition of the system 
to characterization of the locus responsible for the antigen 
at a chromosomal level. Much of this seminal work was 
performed in the Winnipeg Rh Laboratory. So it is not 
surprising that their detailed investigations of the genetic 
mapping of chromosome 1 contributed significantly to 
the progress on SC. Their unique access to informative 
kindreds certainly hastened this process, and in a series 
of reports from 1976 to 1978, linkage between RH and SC 
was established, showing a logarithm of the odds ratio 
(LOD score) of 5.34 at a recombination fraction, θ = 0.10 if 
paternally segregated,11 and the relative position of SC was 
determined12–14 and refined.15
A Third Antigen in the System: Sc3 or Scianna Null 
Alleles
The appearance of “minus-minus” phenotypes, i.e., 
individuals whose RBCs tested negative for both Sc1 and the 
antithetical Sc2 antigen (Sc:–1,–2), was first documented 
in 1973 and demonstrated the existence of apparent SC 
null alleles.16 However, the term Sc3 was not coined until 
1980 when an antibody from an Sc:–1,–2 individual 
demonstrated no evidence of a separable anti-Sc1 or anti-
Sc2.17 The index patient examined in 1973 was a female 
surgical patient from the Likiep Atoll in the Marshall 
Islands, who had been transfused 7 months earlier without 
crossmatching difficulty. Her cells phenotyped as Sc:–1,–
2 as did those from one cousin, but both women’s RBCs 
could still adsorb anti-Sc2. Despite four pregnancies with 
an Sc:1,–2 husband, the proband’s cousin had a negative 
antibody screen. Because these RBCs reduced the titer of 
anti-Sc2, but not anti-Sc1, they may have had some weak 
Sc2 expression, and a new antigen was not definitively 
characterized at that time.
However, in 1980, a 67-year-old man in New York being 
treated with chemoradiotherapy for metastasis to the throat 
of a carcinoma of unknown origin required a preoperative 
transfusion, and demonstrated a positive antibody screen.17 
He had been transfused 4 years earlier without event. 
Unlike the Likiepian Sc:–1,–2 erythrocytes, RBCs from this 
patient did not reduce the titer of either anti-Sc1 or anti-
Sc2. When tested against the Likiepian Sc:–1,–2 cells, the 
New York serum did not agglutinate the RBCs. No other 
Sc:–1,–2 cells were found in a family study. No separable 
anti-Sc1 was present in this patient’s serum, which is 
somewhat unusual because patients who completely lack all 
known antigens for a blood group and have been transfused 
typically make a polyclonal mixture of antibodies directed 
at the common epitopes of that system.18
The next report of a null phenotype for SC was described 
in 1986, in another Pacific Islander.19 This patient was a 
4-year-old girl from Papua New Guinea with thalassemia 
major who had been transfused many times. Anti-Sc3 was 
demonstrated. Erythrocytes from the patient’s mother 
were compatible, and both mother and daughter were 
found to have the Sc:–1,–2 phenotype. In this community, 
the Sc:–1,–2 phenotype was surprisingly common: A survey 
of 29 family members and apparently unrelated villagers 
revealed 6 others (2 of whom had no obvious relationship 
to the patient) who were also Sc:–1,–2. This very high 
phenotype prevalence (20.6%) makes heterozygosity for 
a putative recessive Sc3 allele in the patient’s father quite 
likely (although his RBC phenotype is not reported in the 
short abstract), as well as explaining the homozygosity for 
the same allele observed in her mother.
Additional Sc:–1,–2 individuals have been reported 
(including a patient who experienced an apparent delayed 
hemolytic transfusion reaction), some of whom have also 
lacked several other high-prevalence antigens.18 Evidence 
that each patient in their series produced antibodies with 
different specificities is discussed in Antibodies section.
Radin: A “New” Low-Prevalence Antigen Is Linked to 
Scianna (via RH)
When Radin was first described, in 1967,20 the 
relationship between Radin and Scianna was not 
appreciated. Although the clinical significance of antibodies 
generated to antigens within the SC system in general 
is controversial, the analysis of the antibodies that led to 
the discovery of the Radin antigen is based on its clinical 
importance, with the initial description encompassing 
five cases of mild to moderate hemolytic disease of the 
newborn, of which one required exchange transfusion and 
one appeared in the first pregnancy.20 Additional cases 
and confirmation of the low general frequency (1 in 205) 
appeared shortly thereafter.21
Once again, it was the unique analysis performed by 
the Winnipeg Rh Laboratory that elucidated the putative 
connection between Radin and SC. Linkage analysis 
of eight propositi in ten nuclear families demonstrated 
linkage between Rd and RH.22 Similar to the Sc1/Sc2 
linkage analysis in the present dataset, the Winnipeg 
analysis demonstrated heterochiasmy, with the paternal 
LOD score exceeding 3 at a recombination fraction, θ = 
0.10, whereas the corresponding maternal LOD neither 
suggests nor refutes linkage (LOD = 0.41 at θ = 0.10 ). 
This finding was only sufficient to propose the connection 
between SC and Rd, as heterozygotes at both of these (i.e., 
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double recombinants) had not been found. Incorporation of 
the gene encoding the Rd antigen into the bigger picture of 
chromosome 1 mapping placed it so close to SC that it was 
proposed even at that time that the gene encoding Rd “is 
either very closely linked to or identical with SC.”23
There were few additional reports on the SC blood group 
system for more than 20 years until its molecular basis was 
finally resolved in 2003.1 Since then, molecular analysis 
has identified the three additional alleles underpinning 
the three antibodies described by Devine and coworkers in 
1988.18
Molecular Basis
The ERMAP Expresses the SC Antigens
The molecular basis of the SC blood group system was 
identified in 2003 by merging the genetic mapping data 
with protein chemistry showing that the SC antigens were 
on a single glycoprotein of approximately 60 to 68 kDa 
that must be expressed by RBCs.24,25 The SC gene had been 
mapped to chromosome 1, and based on its linkage to the 
RH genes, the chromosomal location had been further 
refined to 1p34 to 1p36. This led to the identification of a 
strong candidate gene.1
The ERMAP is a 475-amino acid, type 1 single-pass 
membrane glycoprotein that is a member of the butyrophilin 
(BTN) family and is encoded by the ERMAP gene.26,27 It 
consists of a predicted signal sequence of 29 amino acids 
at the NH3 terminus, an extracellular immunoglobulin 
V domain (amino acids 50–126), a short transmembrane 
domain spanning amino acids 157 through 176, and an 
intracellular carboxyl terminus encompassing a B30.2 
domain from amino acids 238 through 395.1
The nomenclature for the transcripts of ERMAP is 
complicated and has been revised many times. At least 
two transcript variants have been described, which 
result from use of an alternative upstream promoter 
and alternative splicing.28 The longer variant is 3,423 
bp and is designated as transcript 1, or as transcript b 
by GenBank curators,29 as it was the second transcript 
variant identified, and it includes an additional upstream 
exon (GenBank NM_001017922.1). The shorter variant is 
designated as transcript 2 or as transcript a, is 3,369 bp, 
excludes this upstream exon (GenBank NM_018538.3), 
begins transcription 45 bp upstream from the start of exon 
2, and was the first variant discovered; thus, early reports 
describe this gene as consisting of 11 exons. However, the 
revised current nomenclature for this gene is based on the 
presence of 12 exons spanning approximately 28 kb. The 
relative production of these two mRNAs is not known, nor 
has it been determined whether the use of either promoter 
is favored in some tissue types or physiologic conditions. 
Both transcripts share the common ATG start codon in 
exon 3; thus, there is no predicted difference in the protein 
product of the two transcripts. They differ in both the 
transcript initiation site and the DNA stretch of exon 2 that 
becomes part of the final transcript; consequently, there are 
two alternative exon 2s, named exon 2a and exon 2b. The 
longer transcript 1 comprises exon 1, exon 2b, and exons 
3 through 12, whereas the shorter transcript 2 starts with 
exon 2a and also includes exons 3 through 12 (Fig. 2).
The Ensembl genome browser curators have delineated 
five transcripts in ERMAP,30,31 three of which are protein 
coding and two of which generate a processed transcript only. 
Two of the Ensembl transcripts correspond to GenBank’s 
transcripts 1 and 2; however, unique to the Ensembl 
database is a 3,949-bp transcript (named ERMAP-002),31 
which is reported as protein coding and generates a short 
protein encoding 385 amino acids rather than the usual 
475. However, only the two transcripts that encode the 
475–amino acid protein are included in the Consensus 
Coding Sequence Project (CCDS; both with identification 
number CCDS475), so the biological significance of the 
3,949-bp transcript is unclear.
In addition to explaining the Sc1/Sc2 biallelic 
single nucleotide polymorphism (SNP) at Gly57Arg, a 
binucleotide GA deletion was identified at nt307 (now 
known as SC*03N.01, provisional name suggested by 
the ISBT Working Party on Red Cell Immunogenetics 
and Blood Group Terminology). This deletion causes a 
frameshift and premature stop codon, which explain the 
SC null phenotype.1 The Rd antigen (Sc4) was defined as 
the Pro60Ala variation, and two other variants in the 
presumed leader signal peptide (54C>T and 76C>T) were 
described in the original study elucidating the molecular 
basis by Wagner and colleagues1 (Table 2).
Understanding the Variants Discovered in the Post-
ERMAP Era
The knowledge of the gene responsible for the antigens 
of this blood group protein opened the floodgates through 
which variant descriptions of unknown, unresolved sero-
logic cases promptly flow. This was clearly the case for SC, for 
which three new variants were discovered within just a few 
years after the characterization of ERMAP as the SC gene. 
Careful molecular follow-up of the three patients described 
by Devine and coworkers18 in 1988 revealed three distinct 
ERMAP/SC variants, demonstrating the importance of 
molecular testing in the resolution of serologic SC mysteries. 
The success of these investigations depended not only on 
the cooperation among an international collaborative, but 
also on the supportive participation of two patients and 
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a family who kindly released two autologous RBC units. 
It was appreciated in the initial case reports in 1988 that 
the SC protein carried multiple high-prevalence antigens 
other than Sc1/2.18 Sera or eluates from these three Sc:1,–2 
patients who had developed high-prevalence antibodies did 
not react with the Sc:–1,–2 null RBCs, but the samples were 
not mutually compatible.
Sc5 (STAR)
In 1982, a 65-year-old man with a history of transfusion 
of three units of crossmatch-compatible whole blood 
before presentation underwent routine preoperative blood 
bank testing, demonstrating anti-C and anti-e. He was 
transfused with another three units of C–e– RBCs, and 1 
week later, a new anti-Jkb and an antibody against a high-
prevalence antigen were detected. Because his serum 
reacted with all cells except his own (phenotyped as Sc:1, 
–2), those of a sibling, and Sc:–1,–2 RBCs, it was suspected 
that he had developed an antibody to another antigen on 
the SC protein.35 Blood needs for the patient were met with 
autologous units. Blood samples from the proband and 16 
family members had been frozen. Sequencing of the exons 
encoding the extracellular and transmembrane domains 
demonstrated homozygosity at a new nonsynonymous 
polymorphism at amino acid 47 (glutamic acid to lysine), 
which is in the N-terminal domain.36 This variation is 
catalogued as rs56047316 in the SNP database (dbSNP), and 
it results from the guanine–adenine transition at nucleotide 
139 in the complementary DNA (cDNA). Frequencies of this 
allele in population studies have not been reported, nor 
have additional cases of this antibody.
Sc6 (SCER) and Sc7 (SCAN)
The remaining two antibody cases described by Devine 
and colleagues18 were concomitantly resolved using the 
same approach as for the Sc5 antigen.37 These investigators 
sequenced all 11 exons of ERMAP known at the time, 
which encompasses all cDNA. They also solicited others to 
submit suspected SC variants and the eight other orphan 
low-prevalence antigens By, Toa, Pta, Rea, Jea, Lia, SARA, 
and Ska. The proband for case 1 reported by Devine and 
colleagues18 demonstrated homozygosity for a guanine–
adenine transition at cDNA nucleotide 242, predicted to 
cause an amino acid change at position 81 (from arginine 
to glutamine), which is in the immunoglobulin V loop.18 
The case 2 proband demonstrated a new homozygous, 
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Fig. 2 Transcripts, exon structure, and variants of erythroid membrane-associated protein (ERMAP). Codon numbers are indicated above 
amino acids involved in described variants. The immunoglobulin variable domain is underlined. Exon 4 is expanded to the nucleotide level 
in the gray box to show the locations of most ISBT-recognized Scianna polymorphisms. The wild-type reference sequence is under the 
corresponding amino acid and is the chromosome 1 reference sequence GenBank NC_000001.10. * = nucleotide deletion.
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Table 2. Erythroid membrane–associated protein polymorphisms in the coding region and global population frequencies
Sc name Descriptive name dbSNP ID: cDNA nt mRNA* Wild-type (WT) Variant Protein effect
Amino acid (aa) 
codon WT aa Variant aa Exon Protein domain Minor allele frequency in blood donors†
rs35757049 11 281 c t nonsynonymous substitution 4 Ala Val 3 Leader 0.054 (dbSNP)
rs33950227 54 324 c t silent 18 Leu Leu 3 Leader 0.28 (German1), 0.1 (dbSNP)
rs33953680 76 346 c t nonsynonymous substitution 26 His Tyr 3 Leader 0.33 (German
1), 0.25 (Caucasian North American32), 0.1 (dbSNP),  
0.05 (African-American32)
Sc7 SCAN 103 373 g a nonsynonymous substitution 35 Gly Ser 4 NH3-terminus
Sc5 STAR rs56047316 139 409 g a nonsynonymous substitution 47 Glu Lys 4 NH3-terminus
Sc1 vs. Sc2 rs56025238 169 439 g (Sc1) a (Sc2) nonsynonymous substitution 57 Gly Arg 4 IgV loop
0.01 (Caucasian North American,33 Brazilian34), 0.008 (German1),  
0.005 (Hispanic American33), 0.002 (African-American33), 0 (Asian American33)
Sc4 Rd rs56136737 178 448 c g nonsynonymous substitution 60 Pro Ala 4 IgV loop 0.003 (Slavs
33), 0.002 (Caucasian North American,33 Danish,21 German,1  
New York Jewish20)
rs33954154 219 489 c t silent 73 Arg Arg 4 IgV loop 0.017 (dbSNP)
Sc6 SCER 242 512 g a nonsynonymous substitution 81 Arg Gln 4 IgV loop
Sc null (D ga together) rs55695242 307 577 g del –1 frameshift 103 Asp frameshift 4 IgV loop
Sc null (D ga together) rs56151267 308 578 a del –1 frameshift 103 Asp frameshift 4 IgV loop
rs35147822 775 1045 t c nonsynonymous substitution 259 Cys Arg 12 B30.2 domain 0.022 (dbSNP)
rs34441268 788 1058 g a nonsynonymous substitution 263 Gly Glu 12 B30.2 domain 0.011 (dbSNP)
rs35972628 888 1158 g a silent 296 Glu Glu 12 B30.2 domain 0.011 (dbSNP)
Sc null 994 1264 c t nonsense (STOP) 332 Arg STOP 12 B30.2 domain
rs55773259 1227 1497 a g silent 409 Leu Leu 12 C-terminus
rs55872827 1324 1594 t c nonsynonymous substitution 442 Ser Pro 12 C-terminus
rs56405033 1355 1625 t c nonsynonymous substitution 452 Leu Pro 12 C-terminus at a 3’ dileucine (LL) phosphorylation motif
rs55677363 1356 1626 g t silent 452 Leu Leu 12 C-terminus at a 3’ dileucine (LL) phosphorylation motif 0.054 (dbSNP)
*NCBI Reference Sequence Position: NM_001017922.1
†Minor allele frequencies for some populations are determined by reports of serologic phenotype and assuming individuals positive for a rare antigen are  
heterozygotes.
cDNA = complementary DNA; dbSNP = single nucleotide polymorphism database; IgV = immunoglobulin V; mRNA = messenger RNA; nt = nucleotide. 
nonsynonymous variant at cDNA nucleotide position 103 
(again a guanine–adenine transition), corresponding to 
a glycine to serine change at amino acid 35 in the NH3 
terminus. This specimen also demonstrated two other SNPs 
(at cDNA nucleotides 54C>T and 76C>T), which had been 
previously reported, are common in Caucasian populations, 
and are in tight linkage disequilibrium (LD).1 Because these 
variants are both in the predicted leader sequence (and the 
54C>T is a silent mutation), they are not predicted to directly 
impact on ERMAP structure. This report also excluded the 
eight orphan low-prevalence antigens from the SC system 
because the only variants found were in the leader sequence 
or in introns.
Molecular Basis of SC Null Phenotypes
Central to the set of specimens originally reported with 
the discovery of ERMAP as SC was an Sc:–1,–2 sample 
from a Saudi Arabian pedigree,1 which demonstrated 
homozygosity at three SNPs: the common 54C>T and 
76C>T (described in an earlier section) as well as a 2-bp 
deletion starting at cDNA nucleotide 307 (307Δga) that 
is predicted to cause a frameshift mutation and early 
termination codon after 113 amino acids. The nt54 and nt76 
SNPs were genotyped in an additional 111 European blood 
donors and were found in tight LD. The frameshift would 
account for a complete lack of an intact ERMAP protein in 
the cell membrane.
Two Sc:–1,–2 individuals from northern and southern 
California were then sequenced in a follow-up study,37 and 
both shared a new SC null allele formed by a nonsense 
mutation at codon 332. This is the first report of a variant 
in the B30.2 intracellular domain in a patient immunized 
to SC. It is not, however, the only variant in the B30.2 
domain (Table 2), because three others have been described 
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in dbSNP, two of which are nonsynonymous amino acid 
changes (C259R and G263E) and one of which is silent 
(E296E). This result suggests that an early translation 
termination, even as late as at codon 332 of the expected 
475, sufficiently interferes with correct protein trafficking, 
membrane insertion, or stability so as to render the 
individual susceptible to alloimmunization at the Sc1/2 site 
(codon 57).
Other Variants in ERMAP: Using dbSNP and HapMap
Variants in the coding region, particularly those in the 
extracellular domain of transmembrane proteins, are of 
particular clinical interest in transfusion medicine, as their 
location provides an obvious mechanism for putative clinical 
significance by alloimmunization. However, much variation 
in the human genome is found outside of coding regions, 
and ERMAP is no exception. Studies of this variation are a 
critical tool in the investigation of human disease and basic 
sciences. Several collaborative projects in human genomics 
focus on gathering, sharing, and interpreting human 
genetic variation, and although a full cataloguing of these is 
beyond the scope of this review, we will present variants in 
ERMAP that are part of two such projects: dbSNP38 and the 
International HapMap Project.39 Table 2 integrates some of 
these variants (identified by their rs numbers) with those 
described in the transfusion medicine literature. These 
data allow informative LD studies of ERMAP (Fig. 3). This 
LD map shows two distinct LD blocks that correspond to 
the exons encoding the extracellular immunoglobulin-like 
domains and the intracellular B30.2 domains of ERMAP. 
The importance of this pattern of LD is that it reveals a 
possible evolutionary vestige of the modular nature of the 
butyrophilin-like (BTNL) protein family and is even more 
pronounced in the Nigerian population. Long stretches of 
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Table 2. Erythroid membrane–associated protein polymorphisms in the coding region and global population frequencies
Sc name Descriptive name dbSNP ID: cDNA nt mRNA* Wild-type (WT) Variant Protein effect
Amino acid (aa) 
codon WT aa Variant aa Exon Protein domain Minor allele frequency in blood donors†
rs35757049 11 281 c t nonsynonymous substitution 4 Ala Val 3 Leader 0.054 (dbSNP)
rs33950227 54 324 c t silent 18 Leu Leu 3 Leader 0.28 (German1), 0.1 (dbSNP)
rs33953680 76 346 c t nonsynonymous substitution 26 His Tyr 3 Leader 0.33 (German
1), 0.25 (Caucasian North American32), 0.1 (dbSNP),  
0.05 (African-American32)
Sc7 SCAN 103 373 g a nonsynonymous substitution 35 Gly Ser 4 NH3-terminus
Sc5 STAR rs56047316 139 409 g a nonsynonymous substitution 47 Glu Lys 4 NH3-terminus
Sc1 vs. Sc2 rs56025238 169 439 g (Sc1) a (Sc2) nonsynonymous substitution 57 Gly Arg 4 IgV loop
0.01 (Caucasian North American,33 Brazilian34), 0.008 (German1),  
0.005 (Hispanic American33), 0.002 (African-American33), 0 (Asian American33)
Sc4 Rd rs56136737 178 448 c g nonsynonymous substitution 60 Pro Ala 4 IgV loop 0.003 (Slavs
33), 0.002 (Caucasian North American,33 Danish,21 German,1  
New York Jewish20)
rs33954154 219 489 c t silent 73 Arg Arg 4 IgV loop 0.017 (dbSNP)
Sc6 SCER 242 512 g a nonsynonymous substitution 81 Arg Gln 4 IgV loop
Sc null (D ga together) rs55695242 307 577 g del –1 frameshift 103 Asp frameshift 4 IgV loop
Sc null (D ga together) rs56151267 308 578 a del –1 frameshift 103 Asp frameshift 4 IgV loop
rs35147822 775 1045 t c nonsynonymous substitution 259 Cys Arg 12 B30.2 domain 0.022 (dbSNP)
rs34441268 788 1058 g a nonsynonymous substitution 263 Gly Glu 12 B30.2 domain 0.011 (dbSNP)
rs35972628 888 1158 g a silent 296 Glu Glu 12 B30.2 domain 0.011 (dbSNP)
Sc null 994 1264 c t nonsense (STOP) 332 Arg STOP 12 B30.2 domain
rs55773259 1227 1497 a g silent 409 Leu Leu 12 C-terminus
rs55872827 1324 1594 t c nonsynonymous substitution 442 Ser Pro 12 C-terminus
rs56405033 1355 1625 t c nonsynonymous substitution 452 Leu Pro 12 C-terminus at a 3’ dileucine (LL) phosphorylation motif
rs55677363 1356 1626 g t silent 452 Leu Leu 12 C-terminus at a 3’ dileucine (LL) phosphorylation motif 0.054 (dbSNP)
*NCBI Reference Sequence Position: NM_001017922.1
†Minor allele frequencies for some populations are determined by reports of serologic phenotype and assuming individuals positive for a rare antigen are  
heterozygotes.
cDNA = complementary DNA; dbSNP = single nucleotide polymorphism database; IgV = immunoglobulin V; mRNA = messenger RNA; nt = nucleotide. 
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LD such as that illustrated in the extracellular domain of 
ERMAP, where all of the SC antigens are encoded, raise the 
possibility that a selective advantage by genetic hitchhiking 
may be operating at ERMAP.40
Global Variation
Some ethnographic trends have already been 
historically appreciated with SC variants during the early 
years of their investigation (Table 2). For instance, Sc4 has 
been identified most often in Ashkenazi Jews and Slavic 
populations, and the few Sc:–1,–2 phenotypes have been 
reported particularly in populations from Oceania. Sc2 
appears to be more common in a consanguineous Canadian 
Mennonite population (derived from a small region in 
Eastern Europe),5 but it remains very rare in or absent from 
populations of African5,33 or Native American10 descent. 
However, it is not sufficient to rely on case reports to 
propose generalizations regarding population frequencies. 
Fortunately, recent technologies are available to rapidly 
genotype ERMAP variants using an automated genotype-
calling platform, and additional population studies will 
continue to be reported.33
Biochemistry and Physiology
ERMAP Is a Member of the Butyrophilin-like Family of 
the Immunoglobulin Superfamily
By virtue of its extracellular immunoglobulin V and 
the intracellular B30.2 domains, ERMAP is a member 
of the BTNL protein family, which is a subset of the 
immunoglobulin superfamily.41 The compact, globular 
110–amino acid immunoglobulin domain defines this 
superfamily and is found in three operational domain 
subclasses: variable (immunoglobulin V), intermediate 
(immunoglobulin I), or constant (immunoglobulin C).42,43 
These proteins are central to many immunologic processes, 
especially cell adhesion, costimulation, and signalling.44,45 
The immunoglobulin superfamily is one of the largest in 
all eukaryotic organisms.46 Other members of this family 
well known to the transfusion medicine community 
Fig. 3 Pairwise linkage disequilibrium (LD) heat plot of the logarithmic odds ratio (LOD) score for single nucleotide polymorphisms in 
erythroid membrane–associated protein (ERMAP) in a Nigerian population. Darker shades (black) = areas of high LD, lighter shades (light 
gray) = areas of lower LD. The areas of tightest LD correspond to the extracellular domains of ERMAP, on the left-hand side of the figure. 
Increased LD is also seen in the intracellular domains, at the right side. This segmental pattern of LD reveals a possible evolutionary vestige 
of the modular nature of the butyrophilin-like protein family. YRI = Yoruba in Ibadan, Nigeria. (Source: Haploview™ software run at http://
hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap3r2_B36/#search; accessed April 27, 2010.)
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include the Lutheran, LW, OK, JMH, and Indian blood 
groups, which are found on the B-CAM, ICAM4, CD147, 
CD108, and CD44 molecules, respectively.47 BTN proteins 
are within the B7-CD28-like branch of this superfamily48 
and have been extensively studied in cows.49 The prototype 
of the human BTN family of proteins is BTN1A1, which is 
primarily expressed in the lactating breast, where it makes 
up 20 percent of the protein in the membrane of milk 
fat globules. The name derives from the Greek butyros 
and philos, meaning “having an affinity for butterfat.” 
Although ERMAP is carried on chromosome 1, the genes 
for many members of this family are located in the major 
histocompatibility complex (MHC) on chromosome 6.50
The lactational and immunologic functions of BTNs 
as a part of the secretory granule-to-plasma membrane 
zipper complex and as an inhibitor of T-cell activation are 
only recently described,51,52 and even less is known about 
the BTNL proteins. There are six known human BTNL 
proteins, which are defined by their homology to BTN 
proteins (Fig. 4). The most extensively studied of these is 
BTNL2, the gene for which is located in the MHC class II 
cluster at 6p21.3. A truncating splice site mutation in BTNL2 
has been associated with sarcoidosis,53 and although this 
SNP has been investigated in many other infectious and 
autoimmune diseases, some of these associations have 
been attributable to LD with the MHC.54 BTNL2 inhibits 
T-cell activation by inhibiting proliferation in response to 
the stimulatory T-cell receptor signal.55 This inability for 
BTNL2 to propagate a cell signal has led some investigators 
to propose its role as “decoy receptor” because it lacks the 
B30.2 intracellular domain present in most other BTN and 
BTNL proteins.54
The B30.2 Cytoplasmic Domain: A Role in 
Erythropoiesis?
The B30.2 (or PRYSPRY) domain was described in 1993 
with the discovery of an exon in the MHC class I region 
showing similarity to other mammalian and amphibian 
proteins, which have since been termed the tripartite 
motif family.56,57 Such a domain was demonstrated in 
bovine BTN58 and in human BTN proteins.59 The B30.2 
domain is proposed to be a recent evolutionary adaptation 
in the immune system of mammals as a fusion of two 
ancient domains (PRY and SPRY), which are found in 
all eukaryotes.50 The genes for proteins in this family 
have a modular structure, suggesting that they arose 
by duplication.56 Mutations in the B30.2 domain in the 
tripartite motif–branch of the B30.2 proteins have been 
associated with Opitz syndrome (MID1 protein) and 
familial Mediterranean fever (pyrin protein). However, 
human syndromes have not been associated with mutations 
in the B30.2 domain of the BTN or BTNL families.
Fig. 4 The organization of the butyrophilin-like (BTNL) family in 
comparison to the butyrophilin (BTN) and B7 families. The B7 
branch of the immunoglobulin superfamily is characterized by 
variable (IgV) and constant (IgC) immunoglobulin domains. The 
BTN subfamily includes the B30.2 intracellular domain. The BTNL 
proteins exhibit various combinations of these features. MOG = 
myelin oligodendrocyte glycoprotein, an autoantigen implicated in 
multiple sclerosis. (Modified from reference 52.)
Fig.5 On the left, blood from a fish of the genus Notothenia (with 
hemoglobin-containing erythrocytes) and on the right is blood 
from Chaenocephalus aceratus. Icefish transport oxygen strictly in 
physical solution, without a carrier molecule. The recent discovery 
that bloodthirsty (bty), a B30.2-domain–containing protein like 
ERMAP, has dramatically decreased expression in hemoglobinless 
icefish provides a fascinating link between this protein domain and 
erythropoiesis. Courtesy of Professor Guillaume Lecointre.
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The crystal structure of the B30.2 domain of pyrin was 
recently elucidated. A β-barrel consisting of two antiparallel 
β-sheets has been described, forming a central cavity.60 The 
ligand(s) that interact with the B30.2 domain have yet to be 
described, although binding analyses suggest that it is the 
site of protein–protein interactions.61 The crystal structure 
of one other B30.2 domain interacting with a peptide has 
shown that there is a conformationally rigid peptide binding 
pocket (consisting of a core β-sandwich around variable 
loops) binding to a short-sequence motif, which may allow 
multiple intracellular targets to bind.62 Recently, BTN1A1 
has been shown to bind xanthine oxidoreductase via B30.2, 
apparently stabilizing the milk fat globule membrane in 
mammary tissue, but it is also hypothesized to function 
as a novel signaling pathway in nonmammary tissues or 
perhaps in the innate immune system via generation of 
reactive oxygen species.63
A role for B30.2 domains in erythropoiesis has been 
revealed through study of an unlikely model organism: 
Antarctic icefish. These animals are the only vertebrate 
taxon that fails to produce RBCs (Fig. 5), and as such 
have been studied in a hunt for genes important in 
erythropoiesis and cardiovascular biology.64 Using 
this approach, a new B30.2-containing protein, called 
bloodthirsty (bty), was identified in the pronephric kidney 
of a red-blooded Antarctic rockcod (Notothenia coriiceps), 
which was present at levels tenfold higher than those in 
an icefish (Chaenocephalus aceratus).65 Interestingly, 
disruption of bty synthesis in zebrafish suppressed both 
erythrocyte production and hemoglobin synthesis, and 
although interactions between bty and ERMAP have been 
hypothesized, they have not been empirically demonstrated 
(H. William Detrich, personal communication, January 
20, 2010).
Functional Studies of ERMAP
The function of ERMAP itself, however, is not well 
understood. The murine homolog, Ermap, was described 
first and named as such because it was found to be produced 
exclusively in erythroid cells.66 The human homolog was 
characterized shortly thereafter, and Northern blots 
demonstrated high expression in hematopoietic tissues, 
such as fetal liver and bone marrow, with weaker expression 
in peripheral blood leukocytes, thymus, lymph node, 
and spleen.26 Sc1 has been demonstrated on phagocytic 
leukocytes using an antibody absorption technique.67 
Recent RNA array expression analysis supports this 
finding, having detected low levels of ERMAP transcripts 
in leukocytes, especially monocytes; however, quantitative 
protein expression remains to be assessed.54 An in silico 
analysis of nucleotide database searches of human 
expressed-sequence tags using the ERMAP transcript 1 
(GenBank NM_001017922.1) as the probe detected the 
transcript in cDNA libraries from hematogenous tissues, 
such as bone marrow, a chronic myeloid leukemia cell line, 
peripheral blood pool, thymus, spleen, and fetal liver, as well 
as in neural tissues.68 However, it is difficult to definitively 
ascribe transcript production to the nonerythroid cells in 
the neural tissues, as contamination from the vasculature 
cannot be completely eliminated. ERMAP mRNA reaches 
peak levels in fetal liver in the 18th through 20th weeks, 
and it is present from the 15th through 32nd weeks in fetal 
bone marrow, suggesting that ERMAP may be related 
to the migration of erythroid cells to these sites during 
hematopoietic development.69
Additional evidence that ERMAP may be involved in 
erythroid differentiation has been put forward, although 
only abstracts of these reports are available in the English 
literature. Using fluorescent quantitative polymerase 
chain reaction,70 ERMAP expression has been found in 
the K562 cell line, which is derived from chronic myeloid 
leukemia and is of undifferentiated granulocytic lineage.71 
To test the degree of erythroid-specificity of ERMAP 
in hematopoiesis, this group used cytarabine (Ara-C) 
to induce these cells toward erythroid differentiation 
and 12-O-tetradecanoylphorbol-13-acetate to induce 
development toward the macrophage lineage, but found 
an increase in ERMAP mRNA after an Ara-C stimulation 
only.72 This finding suggests that although ERMAP may be 
present on cells of the monocyte/macrophage lineage, its 
functional importance may be limited in these cell types. 
RNA silencing experiments using an ERMAP shRNA/K562 
cell line also reported by this group showed decreased 
ERMAP expression and morphologic features, including 
the relative amounts of surface erythrocyte maturation 
markers, leading the authors to conclude that ERMAP 
shRNA inhibited Ara-C–induced erythroid differentiation.73 
A second model of erythroid differentiation using umbilical 
cord blood with two naturally occurring hormones (namely 
stem cell factor and IL-3) and erythropoietin to provoke 
differentiation also showed a concurrent rise in ERMAP 
mRNA with erythrocyte maturation.74
Many structural features of ERMAP point toward a 
putative role in immunity, perhaps by adhering to other 
cells or pathogens via its extracellular immunoglobulin V 
domain, or by immunoregulatory mechanisms such as the 
modulation of cellular activation signals via B30.2 as is 
observed in its BTN family members.52 Much work is needed 
in this area to better characterize the proteins that interact 
with ERMAP, both extracellularly and intracellularly, 
and to determine whether ERMAP has a central role in 
erythropoiesis itself.
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Antibodies in the System
The discovery of the SC blood group system began 
with and has relied on the detection and investigation of 
alloantibodies. The effects of enzymes and chemicals and 
the in vitro characteristics of SC antibodies were recently 
reported elsewhere.75 In general, SC antigens are resistant 
to ficin plus papain, trypsin, α-chymotrypsin, sialidase, 
and 50 mM dithiothreitol (DTT), and they are sensitive to 
pronase and 200 mM DTT. The exception to this trend is the 
variable sensitivity of Sc4 to trypsin and α-chymotrypsin. 
Enzymatic properties of anti-SCER and anti-SCAN are only 
described in the initial case report as showing no change 
in the strength of antibody activity when tested with RBCs 
that had been treated with ficin, papain, trypsin, ZZAP 
(mixture of 0.1 M DTT plus 0.1% cysteine-activated papain), 
or chloroquine diphosphate.18 Anti-STAR demonstrated 
enhanced reactivity with enzyme-treated RBCs.36 Patients 
or donors in whom an antibody to an SC antigen has been 
reported (Table 3) have been thoroughly reviewed recently.76 
Thirteen of the 19 reports of alloantibodies to SC system 
antigens listed in Table 3 have occurred in cases in which 
they do not appear to manifest a major clinical significance. 
All six of the reports with clinical significance occurred in 
cases of HDFN. All six of the reported autoantibodies to SC 
system antigens in patients were in the context of clinically 
significant autoimmune hemolytic anemia, although five 
of these cases were presented as an abstract only, without 
the full clinical details. Alleles Sc4–7 were not tested in 
any of these cases. Such an investigation is warranted 
because heterozygosity for alleles with weak expression 
in the Rh blood group system has been associated with D 
autoantibodies.86
Clinically important reactions to an erythrocyte 
antibody typically result from significant RBC destruction 
and usually manifest in the patient as a hemolytic anemia or 
HDFN. In the SC system, significant HDFN defined the blood 
group in a patient named Ms. Scianna; however, she also 
had anti-D to account for her severe obstetric complications 
in addition to the anti-Sc1.2 Anti-Sc2 has been reported in 
a case of HDFN requiring simple transfusion in a 20-day-
old infant.83 Importantly, the search for antibodies to low-
prevalence antigens in this patient was only performed 
because the neonate and the mother were ABO-compatible: 
had they been ABO-incompatible, the HDFN would likely 
have been attributed to this, and the anti-Sc2 antibody may 
not have been detected.
The recent availability of recombinant reagents to 
assist in the detection of SC antibodies87 may bring this 
ability into the wider immunohematology arena. This novel 
technique will allow one to appraise the relevance of SC 
antibodies in conjunction with other antibodies and tease 
out their relative clinical importance, which may have been 
previously underestimated. The ERMAP protein has been 
expressed in its native form in a eukaryotic system,87 and 
so although the initial report describes the utility of this 
reagent for detecting the high-prevalence SC antigens, a 
screening protein for low-prevalence antigens Sc2 and Sc4 
would also be feasible.
Some SC alloantibodies (Table 3) resulted in delayed 
serologic transfusion reactions without associated 
hemolysis, including a so-called naturally occurring anti-
Sc4 described in a 55-year-old man without a transfusion 
history.21 Many of these patients were transfused with 
crossmatch-compatible blood without incident. However, 
some surgeries were delayed owing to lack of availability 
of crossmatch-compatible units, and other patients 
were transfused with autologous products in nonurgent 
scenarios.18
The remaining reports of important reactions involving 
SC antibodies are in cases of autoimmune hemolytic 
anemia. Auto-anti-Sc1 and -Sc3 have been eluted from 
direct antiglobulin test–positive RBCs of these patients. In 
many cases, these antibodies were transient and associated 
with decreased expression of SC antigens.79,84 Several 
patients underwent splenectomy in addition to treatment 
with many types of immunosuppressant medications. One 
patient with erythroid hypoplasia and diagnosed with an 
Evans-like syndrome even underwent a total of 20 plasma 
exchanges over the course of 11 weeks.82 After the ninth 
exchange, the antibody was no longer detectable, although 
it reappeared 1 week later. He was finally transfused after 16 
exchanges, despite the continued presence of the antibody, 
with a resultant rise in his hematocrit from 14% to 30%.
Clinical Significance
Is It Worth Phenotype or Genotype Matching?
Of the 23 cases of SC alloantibodies catalogued here 
(Table 3), one case of HDFN83 and one delayed hemolytic 
transfusion reaction (case 2)18 relate sufficient information 
in their reports to convincingly attribute clinical relevance 
to SC antibodies. The HDFN cases described in the initial 
report of the Radin antigen also speak to the potential 
importance of antibodies to Sc4 (especially the case that 
required exchange transfusion); however, these cases are 
not reported in sufficient detail to definitively implicate 
anti-Sc4 to the exclusion of all other causes.20 Even the 
very dramatic presentation of Ms. Scianna’s antibody does 
not incriminate anti-Sc1 as the cause of her poor obstetric 
outcomes, as an anti-D of a higher titer was also found.2 
The fundamental question of when and whether antibodies 
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history Clinical synopsis Other laboratory data
anti-Sc1 Allo Schmidt et al.2 1962 Mrs. N.S. Sc:–1,2 25 F Caucasian HDFN anti-D Multiparous, after 1st baby with 
HDFN.
Impossible to distinguish role of anti-Sc1 in presence of anti-D.
Kaye et al.77 1990 Sc:–1,2 28 F Indian No HDFN Excluded all except  
E and Lu(a)
G2, 1st was uncomplicated with 
negative Ab screen.
Neonate with 3+ DAT, eluted anti-Sc1, but Hgb = 13.5 g/dL and no HDFN. Mother B, R1r; 
infant B, rr; husband Sc:1,–2.
IgG3 subclass; steady rise in ADCC despite constant titer throughout pregnancy; 9 weeks postpartum ADCC 
increased ×4 and titer doubled (16 to 32).
Auto Tregellas et al.78 1979 Sc:1, –2 49 Healthy blood donor. Antibody demonstrated in serum, not in plasma, suggesting autoantibody is only seen when it reacts with a 
coagulation factor; IgG3; very weak DAT (both IgG and C3b), weak anti-Sc1 eluted.
McDowell et al.79 1986 Case 1 Sc:1,–2 Hemolytic anemia 3+ DAT and anti-Sc1 in IAT. Eluates by heat, ether, and glycine acid were nonreactive, but xylene eluate showed 
anti-Sc1.
McDowell et al.79 1986 Case 2 Sc:1,–2  
(1+, but 3+ 2 
years later)
Hemolytic anemia 4 units RBC transfused earlier. Transient Sc antigen weakening: serum from initial presentation reacted 3+ with patient’s RBCs 2 years later.
Owen et al.80 1992 Sc:1,–2 10 months F West Indies Hemolytic anemia Sudden-onset jaundice, pallor, fever with hepatomegaly, Hgb = 4.1 g/dL. AIHA diagnosed, 
treated with steroids and IVIG, transfusion, urgent splenectomy. Transfusion-dependent for 
4 weeks, then steroids stopped 7 months after splenectomy.
DAT+ (IgG and C3d), elevated unconjugated bilirubin, reduced haptoglobin, hemoglobinuria. DAT negative with 
follow-up. Serum and eluate demonstrated anti-Sc1.
Ramsey and 
Williams81
2010 Sc:1 20 F Caucasian Hemolytic anemia, 
acute hemolysis
15 units RBC 3 years earlier 
during chemotherapy, previously 
negative Ab screen.
Hodgkin disease in remission, presented with 3 weeks of fatigue, 2-day Hgb decrease (9.1 
to 5.7 g/dL). Gross hematuria and Tbili = 5.5 mg/dL during 3 units RBC transfusion.
Ab screen 1–2+ in all cells (anti-Sc1 identified). DAT– (hospital), w+ (ref. lab; negative eluate). Posttransfusion 
Hgb = 9.2 g/dL. Anti-Sc1 reacted w+ to patient’s cells. Genotyped SC1/SC1. Patient group O–.
Auto vs. Allo 
not resolved
Steane et al.82 1982 Case 2: pt 
C.D.
22 M Caucasian Not reported. Evans-like syndrome with anemia during a lung infection, 2 years of hospitalizations, 
steroids, splenectomy, immune suppressants. Transfused safely after 16 plasma exchanges.
Reported DAT+ , but “presence of an antibody in his plasma which reacted with all erythrocytes tested except his 
own.” Antibody undetectable after the 9th exchange, but it reappeared, then disappeared after 4 more exchanges.
anti-Sc2 Allo Anderson et al.3 1963 Mr. Char. Sc:1,–2 50 M Caucasian DSTR vs. DHTR 3 units RBC transfused 2 weeks 
earlier.
Carcinoma of the stomach, pretransfusion antibody screen positive. Hemolysis could be the 
reason for the 2nd blood request, but this is not stated.
Whether the patient was hemolyzing and thus required the pretransfusion testing is not stated; therefore, we cannot 
distinguish a DSTR from a DHTR as described in this paper. 
Seyfried et al.6 1966 Four donors Healthy donors iatrogenically immunized for anti-D production.
DeMarco et al.83 1995 Sc:1,–2 29 F Caucasian HDFN Negative maternal  
Ab screen
G0, no transfusion history. Jaundice in infant (Tbili = 14.3 mg/dL) on DOL2, postphototherapy discharged Hct = 45%, 
DOL20 Tbili = 6.5 mg/dL, Hct 17.3% with pallor, tachypnea, tachycardia; transfused 45 mL; 
Hct 4 months later = 36.3% Mother B+; infant B-.
Maternal serum 3+ against paternal RBCs (titer of 64) and Sc:–1,2 RBCs; Paternal RBCs Sc:1,2. Neonate cord blood 
DAT macroscopically + IgG; Neonate peripheral venous blood 2+; Readmission on DOL20 DAT 2+ (polyspec, IgG, and 
C3); Eluate + on paternal and Sc:1,–2 RBCs.
anti-Sc3 Allo McCreary et al.16 1973 Sc:–1,–2 F Likiep Atoll, Marshall 
Islands
Transfused 7 months earlier 
without difficulty.
Preoperative testing. Antibody dropped to below detectable levels shortly after discovery.
Nason et al.17 1980 Sc:–1,–2 67 M Caucasian DSTR Transfused 4 years earlier 
without incident.
Preoperative positive antibody screen for metastatic carcinoma surgery. Not transfused 
owing to deteriorating clinical condition and lack of compatible blood.
Negative DAT, did not adsorb anti-Sc1 or anti-Sc2.
Woodfield et al.19 1986 Sc:–1,–2 4 F Papua New Guinea Many transfusions. Thalassemic with new IgG Ab, mother used as only available donor (also Sc:–1,–2). Patient 
underwent splenectomy.
Antibody was undetectable after splenectomy and not stimulated by use of XM-compatible blood.
Auto Peloquin et al.84 1989 Case 1 weak Sc1 and 
Sc3
64 Hemolytic anemia Lymphoma patient with severe anemia; 5 units incompatible RBCs transfused without 
difficulty.
DAT weak with IgG and C3d, eluates negative. Antibody disappeared within 70 days.
Peloquin et al.84 1989 Case 2 weak Sc1 and 
Sc3
54 Hemolytic anemia 4 units RBCs transfused earlier. Hodgkin disease, CHF, moderate anemia; 6 units incompatible blood transfused without 
difficulty.




Allo Rausen et al.20 1967 Family 1 –Rd Sc:–4 (Rd+) F Russian Jewish HDFN “Newborn with hemolytic 
disease” in 1st and 3rd children.
2 children Rd+, both had HDFN; 1 child Rd–, did not have HDFN. Presumably very mild HDFN, as case detected by “routine anti-globulin testing of cord blood.”
Rausen et al.20 1967 Family 2 –Fl Sc:–4 (Rd+) F African American HDFN severe “Newborn with hemolytic 
disease” in 7th and 9th children.
10 children in pedigree: 5 Rd– with no HDFN; 1st 3 Rd+ without HDFN, last 2 Rd+ with 
HDFN (1st of these requiring exchange transfusion).
Rausen et al.20 1967 Family 3 –Ha Sc:–4 (Rd+) F Northern European HDFN “Newborn with hemolytic 
disease” in 4th child. 
4 children in family: 1 Rd– with no HDFN; 1st 2 Rd+ without HDFN, last 1 Rd+ with HDFN. In the same pedigree, Rd– grandmother of HDN proband had 2 children, 1st Rd+ and 2nd Rd–, neither had HDFN.
Rausen et al.20 1967 Family 4 –We Sc:–4 (Rd+) F Native American HDFN 4 children in family: 1 Rd– with no HDFN; 1st 2 Rd+ without HDFN, last 1 Rd+ with HDFN.
Rausen et al.20 1967 Family –5 Gr Sc:–4 (Rd+) F German Jewish or 
Scotch-Irish
HDFN 5 children in family: 3 Rd– with no HDFN; 1 stillborn (3rd in birth order) followed by 1 Rd+ 
with HDFN.
No description of pathology of the stillborn fetus.
Lundsgaard and 
Jensen21
1968 Mrs. J.P. Sc:–4 (Rd+) 47 F DSTR: No clinical 
evidence of 
hemolysis
Had a 9-year-old child.  
2 units blood transfused during 
gynecologic operation.
Moderately strong DAT (polyspecific and IgG-eluate showed anti-Rd), weakened with time. 
Negative Ab screen  preoperatively.
Patient is O+; 2 weeks after transfusion, strongly reactive antibody screen at new hospital. Her child’s RBCs do not 
react with patient’s posttransfusion plasma.
Lundsgaard and 
Jensen21
1968 Mr. L.C. Sc:–4 (Rd+) 55 M Never transfused or hospitalized. Preoperative positive antibody screen for atoxic goiter surgery. Considered as a “naturally 
occurring antibody.”
Winn et al.85 1976 19 M Caucasian DSTR: No clinical 
evidence of 
hemolysis
anti-Vw Negative DAT, negative Ab screen 
before transfusion.
11 units RBC on 3 dates for gunshot wound surgery (7/5, 7/17, and 8/5). 1 unit found 
incompatible on crossmatch (RT, 37°C, and AHG) but screening RBCs still negative.
anti-Vw accounts for incompatible RT crossmatch.
anti-Sc5 
(anti-STAR)
Allo Devine et al.18 
and Skradski 
et al.35
1988 Case 3 Sc:1,–2 65 M Irish and English DSTR anti-C
anti-e
anti-Jkb
3 units RBC 3 years earlier. 1 week after transfusion of 3 units RBC, Ab screen showed new anti-Jkb and a high-
frequency antigen. DAT–, patient eventually diagnosed with lymphoma and transfused with 
autologous units.
Serum reacted with all cells except Sc:–1,–2, autologous, and the patient’s sibling (phenotype Sc:1,–2). Identity of 
antigen discovered with molecular testing years afterward.
anti-Sc6 
(anti-SCER)
Allo Devine et al.18 1988 Case 1 Sc:1,–2 76 M German DSTR 3 units RBC 12 years earlier; 3 
units RBC 6 years earlier.
Preoperative positive Ab screen for revision of right total hip arthroplasty, procedure 
delayed until autologous units could be collected.
Identity of antigen discovered with molecular testing years afterward.
anti-Sc7 
(anti-SCAN)
Allo Devine et al.18 1988 Case 2 Sc:1,–2 50 M German, English, and 
Native American
DHTR anti-D 3 units RBC 8 years earlier;  
2 units RBC 3 years earlier.
12 days after transfusion of 2 units RBC after orthopedic surgery, patient had decrease in 
hematocrit, pretransfusion Ab screen positive, weakly DAT+ (IgG and C3).
Eluate reacted with all cells except Sc:–1,–2. Antibody no longer detected within 9 months. Identity of antigen 
discovered with molecular testing years afterward.
Ab = antibody; ADCC = antibody-dependent cell-mediated cytotoxicity; AHG = antihuman globulin; AIHA = autoimmune hemolytic anemia; CHF = congestive 
heart failure; DAT = direct antiglobulin test; DHTR = delayed hemolytic transfusion reaction; DOL = day of life; DSTR = delayed serologic transfusion reaction; 
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anti-Sc1.
McDowell et al.79 1986 Case 2 Sc:1,–2  
(1+, but 3+ 2 
years later)
Hemolytic anemia 4 units RBC transfused earlier. Transient Sc antigen weakening: serum from initial presentation reacted 3+ with patient’s RBCs 2 years later.
Owen et al.80 1992 Sc:1,–2 10 months F West Indies Hemolytic anemia Sudden-onset jaundice, pallor, fever with hepatomegaly, Hgb = 4.1 g/dL. AIHA diagnosed, 
treated with steroids and IVIG, transfusion, urgent splenectomy. Transfusion-dependent for 
4 weeks, then steroids stopped 7 months after splenectomy.
DAT+ (IgG and C3d), elevated unconjugated bilirubin, reduced haptoglobin, hemoglobinuria. DAT negative with 
follow-up. Serum and eluate demonstrated anti-Sc1.
Ramsey and 
Williams81
2010 Sc:1 20 F Caucasian Hemolytic anemia, 
acute hemolysis
15 units RBC 3 years earlier 
during chemotherapy, previously 
negative Ab screen.
Hodgkin disease in remission, presented with 3 weeks of fatigue, 2-day Hgb decrease (9.1 
to 5.7 g/dL). Gross hematuria and Tbili = 5.5 mg/dL during 3 units RBC transfusion.
Ab screen 1–2+ in all cells (anti-Sc1 identified). DAT– (hospital), w+ (ref. lab; negative eluate). Posttransfusion 
Hgb = 9.2 g/dL. Anti-Sc1 reacted w+ to patient’s cells. Genotyped SC1/SC1. Patient group O–.
Auto vs. Allo 
not resolved
Steane et al.82 1982 Case 2: pt 
C.D.
22 M Caucasian Not reported. Evans-like syndrome with anemia during a lung infection, 2 years of hospitalizations, 
steroids, splenectomy, immune suppressants. Transfused safely after 16 plasma exchanges.
Reported DAT+ , but “presence of an antibody in his plasma which reacted with all erythrocytes tested except his 
own.” Antibody undetectable after the 9th exchange, but it reappeared, then disappeared after 4 more exchanges.
anti-Sc2 Allo Anderson et al.3 1963 Mr. Char. Sc:1,–2 50 M Caucasian DSTR vs. DHTR 3 units RBC transfused 2 weeks 
earlier.
Carcinoma of the stomach, pretransfusion antibody screen positive. Hemolysis could be the 
reason for the 2nd blood request, but this is not stated.
Whether the patient was hemolyzing and thus required the pretransfusion testing is not stated; therefore, we cannot 
distinguish a DSTR from a DHTR as described in this paper. 
Seyfried et al.6 1966 Four donors Healthy donors iatrogenically immunized for anti-D production.
DeMarco et al.83 1995 Sc:1,–2 29 F Caucasian HDFN Negative maternal  
Ab screen
G0, no transfusion history. Jaundice in infant (Tbili = 14.3 mg/dL) on DOL2, postphototherapy discharged Hct = 45%, 
DOL20 Tbili = 6.5 mg/dL, Hct 17.3% with pallor, tachypnea, tachycardia; transfused 45 mL; 
Hct 4 months later = 36.3% Mother B+; infant B-.
Maternal serum 3+ against paternal RBCs (titer of 64) and Sc:–1,2 RBCs; Paternal RBCs Sc:1,2. Neonate cord blood 
DAT macroscopically + IgG; Neonate peripheral venous blood 2+; Readmission on DOL20 DAT 2+ (polyspec, IgG, and 
C3); Eluate + on paternal and Sc:1,–2 RBCs.
anti-Sc3 Allo McCreary et al.16 1973 Sc:–1,–2 F Likiep Atoll, Marshall 
Islands
Transfused 7 months earlier 
without difficulty.
Preoperative testing. Antibody dropped to below detectable levels shortly after discovery.
Nason et al.17 1980 Sc:–1,–2 67 M Caucasian DSTR Transfused 4 years earlier 
without incident.
Preoperative positive antibody screen for metastatic carcinoma surgery. Not transfused 
owing to deteriorating clinical condition and lack of compatible blood.
Negative DAT, did not adsorb anti-Sc1 or anti-Sc2.
Woodfield et al.19 1986 Sc:–1,–2 4 F Papua New Guinea Many transfusions. Thalassemic with new IgG Ab, mother used as only available donor (also Sc:–1,–2). Patient 
underwent splenectomy.
Antibody was undetectable after splenectomy and not stimulated by use of XM-compatible blood.
Auto Peloquin et al.84 1989 Case 1 weak Sc1 and 
Sc3
64 Hemolytic anemia Lymphoma patient with severe anemia; 5 units incompatible RBCs transfused without 
difficulty.
DAT weak with IgG and C3d, eluates negative. Antibody disappeared within 70 days.
Peloquin et al.84 1989 Case 2 weak Sc1 and 
Sc3
54 Hemolytic anemia 4 units RBCs transfused earlier. Hodgkin disease, CHF, moderate anemia; 6 units incompatible blood transfused without 
difficulty.




Allo Rausen et al.20 1967 Family 1 –Rd Sc:–4 (Rd+) F Russian Jewish HDFN “Newborn with hemolytic 
disease” in 1st and 3rd children.
2 children Rd+, both had HDFN; 1 child Rd–, did not have HDFN. Presumably very mild HDFN, as case detected by “routine anti-globulin testing of cord blood.”
Rausen et al.20 1967 Family 2 –Fl Sc:–4 (Rd+) F African American HDFN severe “Newborn with hemolytic 
disease” in 7th and 9th children.
10 children in pedigree: 5 Rd– with no HDFN; 1st 3 Rd+ without HDFN, last 2 Rd+ with 
HDFN (1st of these requiring exchange transfusion).
Rausen et al.20 1967 Family 3 –Ha Sc:–4 (Rd+) F Northern European HDFN “Newborn with hemolytic 
disease” in 4th child. 
4 children in family: 1 Rd– with no HDFN; 1st 2 Rd+ without HDFN, last 1 Rd+ with HDFN. In the same pedigree, Rd– grandmother of HDN proband had 2 children, 1st Rd+ and 2nd Rd–, neither had HDFN.
Rausen et al.20 1967 Family 4 –We Sc:–4 (Rd+) F Native American HDFN 4 children in family: 1 Rd– with no HDFN; 1st 2 Rd+ without HDFN, last 1 Rd+ with HDFN.
Rausen et al.20 1967 Family –5 Gr Sc:–4 (Rd+) F German Jewish or 
Scotch-Irish
HDFN 5 children in family: 3 Rd– with no HDFN; 1 stillborn (3rd in birth order) followed by 1 Rd+ 
with HDFN.
No description of pathology of the stillborn fetus.
Lundsgaard and 
Jensen21
1968 Mrs. J.P. Sc:–4 (Rd+) 47 F DSTR: No clinical 
evidence of 
hemolysis
Had a 9-year-old child.  
2 units blood transfused during 
gynecologic operation.
Moderately strong DAT (polyspecific and IgG-eluate showed anti-Rd), weakened with time. 
Negative Ab screen  preoperatively.
Patient is O+; 2 weeks after transfusion, strongly reactive antibody screen at new hospital. Her child’s RBCs do not 
react with patient’s posttransfusion plasma.
Lundsgaard and 
Jensen21
1968 Mr. L.C. Sc:–4 (Rd+) 55 M Never transfused or hospitalized. Preoperative positive antibody screen for atoxic goiter surgery. Considered as a “naturally 
occurring antibody.”
Winn et al.85 1976 19 M Caucasian DSTR: No clinical 
evidence of 
hemolysis
anti-Vw Negative DAT, negative Ab screen 
before transfusion.
11 units RBC on 3 dates for gunshot wound surgery (7/5, 7/17, and 8/5). 1 unit found 
incompatible on crossmatch (RT, 37°C, and AHG) but screening RBCs still negative.
anti-Vw accounts for incompatible RT crossmatch.
anti-Sc5 
(anti-STAR)
Allo Devine et al.18 
and Skradski 
et al.35
1988 Case 3 Sc:1,–2 65 M Irish and English DSTR anti-C
anti-e
anti-Jkb
3 units RBC 3 years earlier. 1 week after transfusion of 3 units RBC, Ab screen showed new anti-Jkb and a high-
frequency antigen. DAT–, patient eventually diagnosed with lymphoma and transfused with 
autologous units.
Serum reacted with all cells except Sc:–1,–2, autologous, and the patient’s sibling (phenotype Sc:1,–2). Identity of 
antigen discovered with molecular testing years afterward.
anti-Sc6 
(anti-SCER)
Allo Devine et al.18 1988 Case 1 Sc:1,–2 76 M German DSTR 3 units RBC 12 years earlier; 3 
units RBC 6 years earlier.
Preoperative positive Ab screen for revision of right total hip arthroplasty, procedure 
delayed until autologous units could be collected.
Identity of antigen discovered with molecular testing years afterward.
anti-Sc7 
(anti-SCAN)
Allo Devine et al.18 1988 Case 2 Sc:1,–2 50 M German, English, and 
Native American
DHTR anti-D 3 units RBC 8 years earlier;  
2 units RBC 3 years earlier.
12 days after transfusion of 2 units RBC after orthopedic surgery, patient had decrease in 
hematocrit, pretransfusion Ab screen positive, weakly DAT+ (IgG and C3).
Eluate reacted with all cells except Sc:–1,–2. Antibody no longer detected within 9 months. Identity of antigen 
discovered with molecular testing years afterward.
Hct = hematocrit; HDFN = hemolytic disease of the fetus and newborn; Hgb = hemoglobin; IAT = indirect antiglobulin test; IgG = immunoglobulin G; IVIG = 
intravenous immunoglobulin; RBCs = red blood cells; RT = room temperature; Tbili = total bilirubin; XM = crossmatch.
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to SC system antigens are of clinical importance remains 
unresolved because these antibodies are not routinely 
characterized, especially if they are detected along with 
other, better-understood alloantibodies that can account 
for a clinical presentation.
On the Detection of SC System Antibodies in Routine 
Pretransfusion Testing
The most important obstacle to understanding the 
clinical consequences of transfusing across SC antigens is 
that serologic reagents to simply define these antigens in 
both patients and test RBCs have not been widely available. 
As they do for the Dombrock blood group system,88 
molecular approaches help resolve these situations. It 
has been estimated that approximately 13 percent of the 
transfused population are immunologic responders capable 
of creating alloantibodies,89 but unless RBC reagents with 
SC antigens are included in the routine laboratory workup, 
these antibodies may go unnoticed. It is also problematic 
if an antibody to one of the high-prevalence SC antigens is 
in fact detected because the mere presence of the antibody 
does not necessarily correspond to clinical importance. 
Such a qualitative assay is insufficient. The quantitative 
characterization of the antibody, such as by titer, has 
only been performed in a few SC antibody cases, and we 
recommend that this parameter be more routinely evaluated 
in cases of possible hemolysis caused by antibodies in the SC 
system and in most other blood group systems. Especially 
because HDFN has been reported, establishing a better 
understanding of antibody potency as detected by the titer 
would help inform practice guidelines.
An economic and rational approach would be 
the routine use of recombinant SC protein during 
pretransfusion testing before titration to effectively screen 
only for antibodies present above a threshold titer.87 In 
this way, nuisance antibodies (akin to the low-titer cold 
autoantibodies detected before routine testing at higher 
temperatures) would fall under the radar as desired and 
precious laboratory resources would not be spent working 
up these most likely incidental findings. Only higher titer 
antibodies would be detected, focusing the laboratory 
investigation on cases more likely to be of consequence to 
the patient. If these laboratory techniques do lead to the 
increased identification of SC system alloantibodies, the 
medical importance of respecting them in a particular 
patient’s transfusion recommendation remains debatable.
Should We Genotype for SC Alleles?
The integration of molecular diagnostics with trans-
fusion medicine has been a slow, but steady, process, with 
applications ranging from individual patient prenatal 
diagnosis to routine high-throughput donor testing.90,91 
Although the rate of implementation of these technologies 
varies among nations92 and local transfusion services,93 it is 
expanding.94 The transfusion community should move these 
procedures from potentially inaccessible research laboratories 
to standard clinical practice.95 For optimal performance of 
such an approach toward personalized medicine, ideally all 
donors and all recipients should be evaluated at a molecular 
level. Economic barriers to this strategy are falling as high-
throughput and multiplexed assays are achieved, because 
the incremental cost of adding a handful of additional SNPs 
when designing a DNA microarray is negligible. Consequently, 
molecular testing strategies are shifting from decisions about 
which variants to include in a genotyping system that force the 
prioritization of well-studied variants already known to have 
medical importance, to finding effective platforms to analyze 
data derived from genotyping as many known variants as 
possible, regardless of their allele frequencies or uncertain 
clinical effects.
The most compelling reason to genotype SC variants in 
greater depth, both by increasing the number of donors and 
patients and also by including more variants regardless of 
their prevalence, is that such data are necessary to clarify 
the presently ambiguous role of SC in clinical transfusion 
practice. At the same time, valuable data for research into 
ERMAP biology are accrued without added costs. Inclusion 
of the SC*01 to SC*07 alleles in high-throughput assays 
would be a move in the right direction, and in cases of 
unresolved serology, a referral to the molecular laboratory 
for an in-depth investigation may be desirable. By using 
a high-throughput genetic test to determine the potential 
for alloimmunization by a variant homozygote, we can 
collect such genetic data almost for free. The pursuit of 
alloantibodies in such variant homozygous patients is 
a feasible strategy to achieve complete resolution of all 
alloantibodies in a posttransfusion sample submitted as a 
transfusion reaction investigation. Consequently, knowing 
these genetic data gives us the opportunity to better define 
which antibodies are of clinical importance.
Conclusion
The SC story is an excellent example of the essential 
roles that classical genetics played in the original physical 
mapping of a blood group system and is an exceptional 
illustration of transfusion laboratories that were in the right 
place at the right time to finally identify the responsible 
locus in the era of whole genome analysis. Parsing out the 
meaning of global polymorphism frequency distributions 
in light of founder effects or selection pressures would be 
a useful adjunct to in vitro studies of transcript utilization 
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and protein expression and function. The continued 
study of ERMAP homologues, such as the BTNL family of 
proteins in general, and their physiologic interactions in 
other species, such as the B30.2-containing bloodthirsty 
gene in Antarctic icefishes, is a promising avenue to explore 
fundamental insights into erythropoiesis. Investigators 
in transfusion medicine are uniquely poised not only to 
carry out this work but also to lead the way toward a more 
comprehensive understanding of the “lucky 13th” blood 
group, SC, making us the lucky ones indeed.
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